1. Report Overview

1.1 Global Drug Discovery Outsourcing Market Overview

1.2 Market Definition & Scope

1.3 Overview of Findings

1.4 Structure of the Report

1.5 Why You Should Read This Report?

1.6 Key Questions Answered by This Analytical Report

1.7 How This Report Delivers

1.8 Who is This Report For?

1.9 Methodology

1.9.1 Primary Research

1.9.2 Secondary Research

1.9.3 Market Evaluation & Forecasting Methodology

1.10 Frequently Asked Questions (FAQ)

1.11 Associated Visiongain Reports

1.12 About Visiongain

2. An Introduction to Drug Discovery Outsourcing

2.1 What is Outsourcing?

2.2 What is Drug Discovery Outsourcing?

2.3 Why Outsource Drug Discovery?

2.4 A Common Drug Discovery Model Includes Pharmaceutical Organizations Collaborating with Academia

2.5 The Outsource Model for Drug Development Increases Innovation

2.6 Outsourced Processes in Drug Discovery

2.7 Challenges with Drug Discovery Outsourcing

2.8 Emerging Markets are a Popular Destination for CROs

2.9 Strategic Partnerships to Acquisitions

2.10 Recent Drug Development Outsourcing Agreements

3. Global Drug Discovery Outsourcing Market and Service Area Submarkets: Market Forecast to 2028

3.1 Drug Discovery Outsourcing: Global Market Overview

3.2 The Global Drug Discovery Outsourcing Market: Revenue Forecast to 2028

3.3 Global Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028

3.4 Global Drug Discovery Outsourcing Market by Region: Revenue Forecast to 2028

4. Global Drug Discovery Outsourcing Market by Service Type: Forecast to 2028

4.1 The Global Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028

4.2 Chemistry Services

4.2.1 Libraries

4.2.2 Building Blocks

4.2.3 Compound Synthesis

4.2.4 Global Drug Discovery Outsourcing Market: Chemistry Services Revenue Forecast to 2028

4.3 Biology Services

4.3.1 Target Identification

4.3.2 Target Validation

4.3.3 Global Drug Discovery Outsourcing Market: Biology Services Revenue Forecast to 2028

4.4 Lead Optimisation

4.4.1 ADMET Screening: Prevents Late Stage Failure of Clinical Trials

4.4.2 Global Drug Discovery Outsourcing Market: Lead Optimisation Revenue Forecast to 2028

4.5 Lead Identification and Screening

4.5.1 Methods of Screening in Drug Discovery

4.5.2 Primary Screening

4.5.3 Global Drug Discovery Outsourcing Market: Lead Identification and Screening Revenue Forecast to 2028

5. Global Drug Discovery Outsourcing Market by Regional and National Market: Forecast to 2028

5.1 Drug Discovery Outsourcing Overview

5.2 The Leading National Markets in the Drug Discovery Outsourcing Market Forecast to 2028

5.3 North America

5.3.1 North America Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028

5.3.2 North America Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028

5.3.3 US Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.3.3.1 Canada Drug Discovery Outsourcing Market, Revenue Forecast to 2028

5.3.3.2 Mexico Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.4 Europe

5.4.1 Europe Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028

5.4.2 Europe Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028

5.4.2.1 Germany Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.4.2.2 France Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.4.2.3 United Kingdom Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.4.2.4 Italy Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.4.2.5 Spain Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.4.2.6 Russia Drug Discovery Outsourcing Market: Revenue Forecast, 2018-2028

5.5 Asia-Pacific

5.5.1 Asia-Pacific Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028

5.5.2 Asia-Pacific Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028

5.5.3 Japan Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.5.4 China Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.5.4.1 Challenges to China’s Growth

5.5.5 Australia Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.5.6 South Korea Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.5.7 India Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.6 LAMEA

5.6.1LAMEA Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028

5.6.2 LAMEA Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028

5.6.3 Brazil Drug Discovery Outsourcing Market: Revenue Forecast to 2028

5.6.4 Saudi Arabia Drug Discovery Outsourcing Market, Revenue Forecast to 2028

5.6.5 Republic of South Africa Drug Discovery Outsourcing Market: Revenue Forecast to 2028

6. Leading Companies in Drug Discovery Outsourcing Market

6.1 Drug Discovery Outsourcing: A Fragmented and Growing Marketplace

6.2 Characteristics of Leading Contract Research Organisations

6.2.1 A Highly Quality Workforce

6.2.2 Emphasis on Intellectual Property Protection

6.2.3 Long Term Working Relationship

6.2.4 Success in Project Completion

6.2.5 Internal Drug Discovery Programmes

6.3 Service Offerings of Leading Companies in the Drug Discovery Outsourcing Market

6.3.1 List of Key Participating Players in Drug Discovery Outsourcing Market

6.3.2 Albany Molecular Research (AMRI)

6.3.2.1 Company Overview

6.3.2.2 Historical Sales and Financial Performance, 2013-2016

6.3.2.3 AMRI’s Drug Discovery Services

6.3.2.4 Internal Portfolio of Drug Discovery and Development Programme Collaborations

6.3.3 Evotec AG

6.3.3.1 Evotec AG Financial Performance, 2013-2017

6.3.3.2 Evotec AG Sales Forecast, 2018-2028

6.3.3.3 Evotec AG Recent Strategic Moves & Development

6.3.3.3.1 Partnership with Boehringer Ingelheim Pharma

6.3.3.3.2 Collaboration with CHDI

6.3.3.3.3 Collaboration with MedImmune

6.3.3.3.4 Collaboration with UCB Pharma

6.3.3.3.5 Collaboration with Janssen

6.3.3.3.6 Partnership with Bayer Pharmaceuticals

6.3.3.3.7 Partnership with AstraZeneca

6.3.3.3.8 Partnership with Johnson & Johnson

6.3.3.3.9 Partnership with Sanofi

6.3.3.3.10 Extended Partnership with Evotec

6.3.3.3.11 Collaboration with TESARO, Inc.

6.3.3.3.12 Collaboration with Petra Pharma Corporation

6.3.3.3.13 Collaboration with Carna Biosciences, Incorporated

6.3.3.3.14 Collaboration with Celgene Corporation

6.3.3.3.15 Partnership with Sanofi

6.3.3.3.16 Collaboration with Bayer AG

6.3.3.3.17 Partnership with Novo Nordisk

6.3.3.3.18 Partnership with CENTOGENE AG

6.3.3.3.19 Collaboration with Almirall, S.A.

6.3.4 Aptuit

6.3.4.1 INDIGO: Accelerating Early Drug Candidates

6.3.4.2 Aptuit Clinical Trial Supplies

6.3.4.3 Strategic Partnerships, Acquisitions and Divestitures

6.3.4.3.1 Divestiture of Aseptic Clinical Manufacturing

6.3.4.3.2 Partnership with Siena Biotech

6.3.4.3.3 Aptuit’s Extended Partnership with GSK for Verona Centre

6.3.4.3.4 Partnership with Laurus Labs

6.3.4.3.5 Collaboration with Celgene Corporation

6.3.4.3.6 Partnership with Chronos Therapeutics

6.3.4.3.7 Partnership with Chiesi Farmaceutici

6.3.4.3.8 Collaboration with the Molecular Surgical Laboratory of Massachusetts General Hospital (MGH)

6.3.4.3.9 Partnership with SAMDI Tech, Inc.

6.3.4.3.10 Collaboration with Bioversys AG

6.3.4.3.11 Partnership with Regulus Therapeutics Inc.

6.3.5 Cyprotex

6.3.6 Charles River Laboratories

6.3.6.1 Historical Sales and Recent Financial Performance, 2013-2017

6.3.6.2 Strategies: Charles River Laboratories

6.3.6.2.1 Acquisition of Galapagos’ CRO Services Division (BioFocus and Argenta)

6.3.6.2.2 Acquisition of VivoPath

6.3.6.2.3 Acquisition of ChanTest

6.3.6.2.4 Partnership with The Milner Therapeutics Institute

6.3.6.2.5 Partnership with Chiesi Farmaceutici SpA

6.3.6.2.6 Partnership with Nimbus Therapeutics

6.3.6.2.7 Partnership with Microbiologics

6.3.6.2.8 Agreement with CAS

6.3.6.2.9 Partnership Extension with Eisai Co., Ltd.

6.3.6.2.10 Agreement with SenzaGen

6.3.6.2.11 Acquisition of Brains On-Line

6.3.6.2.12 Acquisition of KWS BioTest

6.3.6.2.13 Acquisition of MPI Research

6.3.6.2.14 Agreement with AstraZeneca

6.3.6.2.15 Partnership Extension with PathoQuest

6.3.6.3 Charles River Laboratories: Revenue and Financial Analysis, 2017

6.3.6.4 Charles River Laboratories Sales Forecast, 2018-2028

6.3.7 WIL Research Laboratories LLC

6.3.7.1 Focus on Preclinical Research

6.3.7.2 Acquisition of Midwest Bio Research

6.3.7.3 Acquisition of Ricerca Biosciences LLC

6.3.8 Covance (Acquired by Laboratory Corporation of America)

6.3.8.1 Covance: Historical Revenue and Financial Performance, 2010-2013

6.3.8.2 LabCorp Financial Performance, 2014-2017

6.3.8.3 Strategies: Covance

6.3.8.3.1 Agreement with Eli Lilly

6.3.8.3.2 Agreement with Kellogg Company

6.3.8.3.3 Early Stage Discovery Efforts

6.3.8.3.4 Agreement with Sanofi

6.3.8.3.5 Agreement with Bio Pontis Alliance

6.3.8.3.6 Agreement with Indiana Clinical and Translational Sciences Institute (CTSI)

6.3.8.3.7 Launch of Mobile Health Solutions

6.3.8.3.8 Business Expansion in the UK

6.3.8.3.9 Business Expansion in Precision Medicine

6.3.8.3.10 Acquisition of Chiltern

6.3.8.3.11 Introduced Dedicated Offering

6.3.8.3.12 Agreement with GlaxoSmithKline

6.3.8.3.13 Focused Unit on Biologic Drug Development

6.3.8.3.14 Acquisition of Sciformix Corporation

6.3.9 Domainex

6.3.9.1 Drug Pipeline

6.3.9.2 TBK1/ IKKε-Inhibitors

6.3.9.3 Methyltransferase (KMTS) Inhibitors

6.3.10 GenScript Biotech Corporation

6.3.10.1 GenScript: Revenue and Financial Analysis, 2017

6.3.10.2 GenScript: Agreements and Partnerships

6.3.11 Pharmaceutical Product Development (PPD)

6.3.11.1 PPD: Agreements, Strategic Partnerships and Private Merger

6.3.11.1.1 Partnership with GSK

6.3.11.1.2 Partnership with Elan

6.3.11.1.3 Acquisition of Acurian

6.3.11.1.4 Collaboration with Charité–Universitätsmedizin Berlin

6.3.11.1.5 Acquisition of RCT Logic’s Exclusive License

6.3.11.1.6 Partnership with ERT

6.3.11.1.7 Partnership with Shin Nippon Biomedical Laboratories Ltd.

6.3.11.1.8 Collaboration with HealthCore, Inc.

6.3.11.1.9 Collaboration with CISYS LifeSciences

6.3.11.1.10 Collaboration with Moderna Therapeutics

6.3.11.1.11 Acquisition of Evidera

6.3.11.1.12 Collaboration with Frenova Renal Research

6.3.11.1.13 Collaboration with Quotient Sciences

6.3.12 QuintilesIMS (IQVIA)

6.3.12.1 QuintilesIMS: Historical Revenue and Financial Performance, 2013-2017

6.3.12.2 QuintilesIMS: Strategic moves & developments

6.3.12.2.1 Development Deal with Merck

6.3.12.2.2 QuintilesIMS: Acquisition of Advion Bioanalytical Labs

6.3.12.2.3 QuintilesIMS: Shedding Jobs

6.3.12.2.4 Merger with IMS Health

6.3.12.3 QuintilesIMS Sales Forecast, 2017-2028

6.3.13 Selcia

6.3.13.1 A Strong Natural Product Chemistry Track Record

6.3.13.2 Selcia Product Portfolio

6.3.13.3 Selcia Strategic Moves

6.3.13.3.1 Collaboration with Cantab

6.3.13.3.2 Initiative with the University of Edinburgh

6.3.13.3.3 Collaboration with Janssen Pharmaceuticals Inc.

6.3.13.3.4 Collaboration with Gilead Sciences, Inc.

6.3.13.3.5 Collaboration with Parkinson’s UK

6.3.14 Viva Biotech (Shanghai) Ltd.

6.3.15 WuXi Apptec

6.3.15.1 WuxiTec Services & Solutions Offerings

6.3.15.2 WuXiAppTec: Historical Revenue and Financial Performance, 2010-2014

6.3.15.3 WuxiTec: Strategic Moves

6.3.15.3.1 Acquisition of Next CODE Health

6.3.15.3.2 Collaboration with Gilead Sciences, Inc.

6.3.15.3.3 Collaboration with Eli Lilly and Company

6.3.15.3.4 Acquisition of Crelux GmbH

6.3.15.3.5 Collaboration with Pelago Bioscience

6.3.15.3.6 Partnership with AutoGenomics

6.3.15.3.7 Acquisition of HD Biosciences

6.3.15.3.8 Acquisition of ResearchPoint Global

6.3.15.3.9 Partnership with Mayo Clinic

6.3.15.3.10 Collaboration with Regulus Therapeutics Inc.

6.3.15.3.11 Business Expansion in the U.S.

6.3.15.3.12 Partnership with Antengene Corporation

7. Qualitative Analysis of the Drug Discovery Outsourcing Market

7.1 Drivers and Restraints in the Drug Discovery Outsourcing Market

7.2 SWOT Analysis of the Drug Discovery Outsourcing Market, 2018-2028

7.2.1 Strengths

7.2.1.1 Cost Reduction: A Central Driver for Outsourcing

7.2.1.2 Accelerating the Discovery of Drug Candidates

7.2.1.3 Growth of Virtual Pharmaceutical Companies

7.2.1.4 Reduction in R&D capacity Within Big Pharma

7.2.2 Weaknesses

7.2.2.1 Slowing Trajectory of Growth for R&D Spending

7.2.2.2 Increasingly Saturated Market Requires Companies to Quickly Evolve

7.2.3 Opportunities

7.2.3.1 The Available Scope for the Expansion of CROs

7.2.3.2 Targeted Therapies: Advances in Biologics and Orphan Drugs

7.2.3.3 Increasing Development of Biologics and Biosimilars

7.2.4 Threats

7.2.4.1 A Competitive Market is Increasing Consolidation

7.2.4.2 Threat of Private Public Alliances

7.2.4.3 Intellectual Property Leaks

7.2.4.4 Challenges of Technology Transfer

7.3 Porter’s Five Forces Analysis of the Drug Discovery Outsourcing Market

7.3.1 Threat of New Entrants: Medium

7.3.2 Power of Suppliers: Medium

7.3.3 Threat of Substitutes: Medium

7.3.4 Power of Buyers: High

7.3.5 Rivalry Among Competitors: High

8. Conclusion

8.1 Market Overview

8.2 Lead Optimisation will be the Fastest Growing Sector

8.3 The Drug Discovery Outsourcing Market in Emerging Market Shows Huge Gains

8.4 Continued Growth in Alliances and Collaborations

8.5 Concluding Remarks

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

List of Tables

Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2017

Table 2.2 Selected Drug Discovery Outsourcing Alliances, 2013-2018

Table 3.1 PhMRA’s Historical Estimate for its Member’s Total R&D Spending ($bn), 1980–2016

Table 3.2 Global Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), and CAGR (%) 2018-2028

Table 3.3 Global Drug Discovery Outsourcing Market by Service Type: Revenue ($mn), AGR (%) and CAGR (%) 2017-2028

Table 3.4 Global Drug Discovery Outsourcing Market by Leading Nationals: Revenue ($m), AGR (%) and CAGR (%), 2018-2028

Table 4.1 Global Drug Discovery Outsourcing Market: Revenue ($m), Revenue Share (%) by Service Type, 2017, 2023, 2028

Table 4.2 Global Drug Discovery Outsourcing Market: Chemistry Services Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 4.3 Global Drug Discovery Outsourcing Market: Biology Services Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 4.4 Global Drug Discovery Outsourcing Market: Lead Optimisation Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 4.5: Selected Source for Lead Compounds

Table 4.6 Global Drug Discovery Outsourcing Market: Lead Identification and Screening Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.1 Global Drug Discovery Outsourcing Market: Revenue ($m), Revenue Share (%) by Region, 2017, 2023, 2028

Table 5.2 North America Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.3 North America Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.4 US Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.5: Canada Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.6 Mexico Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.7 Europe Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.8 Europe Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.9 Germany Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.10 France Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.11: United Kingdom Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 5.12: Italy Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.13: Spain Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.14: Russia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.15: Asia-Pacific Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.16: Asia-Pacific Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.17: Japan Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.18: China Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.19: Australia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.20: South Korea Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.21: India Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.22: LAMEA Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.23: LAMEA Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.24: Brazil Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.25: Saudi Arabia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 5.26: Republic of South Africa Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 6.1: List of Key Participating Players

Table 6.2: Albany Molecular Research (AMRI): Historical Revenue ($m), 2013-2016

Table 6.3: AMRI: Service Offerings and Descriptions, 2017

Table 6.4: Evotec: Revenue and R&D Expenses ($m), 2013-2017

Table 6.5: Evotec AG Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.6: Selected Cyprotex Partnerships, 2015

Table 6.7: Charles River Laboratories: Historical Revenue ($m), 2013-2017

Table 6.8: Charles River Laboratories: Revenue ($m) by Segment, 2015-2017

Table 6.9: Charles River Laboratories: Revenue & %Change, 2015-2017

Table 6.10: Charles River Laboratories Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2028

Table 6.11: Covance: Historical Revenue ($bn), 2010-2013

Table 6.12: LabCorp: Historical Revenue ($m), 2014-2017

Table 6.13: Domainex Selected Collaborations

Table 6.14: Domainex: Drug Pipeline by Indication, 2018

Table 6.15: GenScript: Business Segments

Table 6.16: GenScript: Revenue by Business Segments ($m, %), 2016 & 2017

Table 6.17: QuintilesIMS: Revenue ($m) & AGR (%), 2013-2017

Table 6.18: QuintilesIMS Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028

Table 6.19: Viva Biotech: Service Offerings

Table 6.20: WuXi AppTec: Historical Revenue ($m), By Business Segments, 2010-2014

Table 7.1 SWOT Analysis of the Drug Discovery Outsourcing Industry, 2017-2027

Table 8.1: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($m), CAGR (%), 2017, 2023 & 2028

Table 8.2: Global Drug Discovery Outsourcing Market, Revenue ($m) by Service Type, 2017, 2023, 2028

List of Figures

Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2017

Figure 2.2 Stages of the Drug Development Cycle

Figure 3.1 PhMRA’s Historical Estimate for its Member’s Total R&D Spending ($bn), 2000–2016

Figure 3.2 Attrition Rate of Compounds at the Developmental Stages

Figure 3.3 Global Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 4.1 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Service Type, 2018

Figure 4.2 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Service Type, 2023

Figure 4.3 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Service Type, 2028

Figure 4.4 Global Drug Discovery Outsourcing Market Revenue ($m) by Service Type, 2018-2028

Figure 4.5 Global Drug Discovery Outsourcing Market: Chemistry Services Revenue ($m), AGR (%), 2018-2028

Figure 4.6 Global Drug Discovery Outsourcing Market: Biology Services Revenue ($m), AGR (%), 2018-2028

Figure 4.7: An Overview of ADMET Screening in Drug Discovery

Figure 4.8 Global Drug Discovery Outsourcing Market: Lead Optimisation Revenue ($m), AGR (%), 2017-2028

Figure 4.8 Typical Steps in the Lead Screening Process

Figure 4.9 Global Drug Discovery Outsourcing Market: Lead Identification and Screening Revenue ($m), AGR (%), 2018-2028

Figure 5.1 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2017

Figure 5.2 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2023

Figure 5.3. The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2028

Figure 5.4 Global Drug Discovery Outsourcing Market Revenue ($m) by Leading Nationals, 2018-2028

Figure 5.5 US Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.6: Canada Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.7 Mexico Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.8 Germany Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.9: France Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.10: United Kingdom Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.11: Italy Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.12: Spain Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.13: Russia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.14: Japan Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2017-2028

Figure 5.15: China Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.16: Australia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.17: South Korea Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.18: India Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.19: Brazil Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.20: Saudi Arabia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 5.21: Republic of South Africa Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028

Figure 6.1: Albany Molecular Research (AMRI): Historical Revenue ($m), 2013-2016

Figure 6.2: Evotec AG Forecast: Revenue ($m), AGR (%), 2017-2028

Figure 6.3: Charles River Laboratories: Historical Revenue ($m), 2013-2017

Figure 6.4: Charles River Laboratories: Revenue Share (%) by Segment, 2017

Figure 6.5: Charles River Laboratories: Revenue & %Change, 2015-2017

Figure 6.6: Charles River Laboratories Forecast: Revenue ($m), AGR (%), 2017-2028

Figure 6.7: Covance: Historical Revenue ($m), 2010-2013

Figure 6.8: Covance: Revenue Share (%) by Segment, 2013

Figure 6.9: LabCorp: Historical Revenue ($m), 2014-2017

Figure 6.10: LabCorp: Revenue Share (%) by Segment, 2017

Figure 6.11: GenScript: Revenue by Business Segments (%), 2017

Figure 6.12: QuintilesIMS: Revenue ($m), 2013-2017

Figure 6.13: QuintilesIMS Forecast: Revenue ($bn), AGR (%), 2017-2028

Figure 7.1: The Drug Discovery Outsourcing Market: Drivers and Restraints, 2018-2028

Figure 7.2: Porter’s Five Forces Analysis of the Companion Diagnostics Market, 2018-2028

Figure 8.1: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($m), 2017, 2023, 2028

Figure 8.2: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($m) by Service Type, 2017, 2023, 2028